Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $32.77

Denali Therapeutics Inc. (NASDAQ:DNLI) has earned an average rating of “Buy” from the sixteen analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $32.7692.

Several research firms recently issued reports on DNLI. Morgan Stanley reissued an “overweight” rating and issued a $40.00 target price on shares of Denali Therapeutics in a report on Thursday, January 8th. UBS Group initiated coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating for the company. JPMorgan Chase & Co. raised their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Denali Therapeutics in a report on Friday, December 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th.

Insider Activity

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DNLI. Capricorn Fund Managers Ltd purchased a new position in Denali Therapeutics during the fourth quarter valued at $1,027,000. Aberdeen Group plc boosted its holdings in shares of Denali Therapeutics by 82.6% during the 4th quarter. Aberdeen Group plc now owns 2,032,967 shares of the company’s stock valued at $33,564,000 after purchasing an additional 919,381 shares during the last quarter. Clarius Group LLC grew its position in shares of Denali Therapeutics by 2.6% during the fourth quarter. Clarius Group LLC now owns 368,995 shares of the company’s stock valued at $6,092,000 after purchasing an additional 9,250 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics by 291.6% in the fourth quarter. SG Americas Securities LLC now owns 149,592 shares of the company’s stock worth $2,470,000 after purchasing an additional 111,391 shares during the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in shares of Denali Therapeutics by 1.7% in the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after purchasing an additional 920 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $20.93 on Tuesday. The stock has a market cap of $3.07 billion, a P/E ratio of -7.19 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The stock’s fifty day moving average is $17.83 and its 200 day moving average is $15.92. Denali Therapeutics has a one year low of $10.57 and a one year high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same period in the previous year, the firm posted ($0.63) earnings per share. Denali Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. Sell-side analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.